Wikipedia -WSS

Wikipedia

author：Wikipedia 2025-09-30 18:59:44 - browse：7

Cell and gene therapy sign seen at a conference. -- biotech coverage from STAT — Jonathan Wosen for STAT

CARLSBAD, Calif. — Biotech CEOs leading cell and gene therapy companies spoke frankly at a conference here last week about the tough choices they’re making to preserve limited cash amid the industry’s ongoing slowdown.

The company leaders said that they’ve felt added pressure to use smaller teams to work quickly on fewer projects, and at times to partner with outside firms that have specific manufacturing and research expertise. Not all of these changes are bad, they added, noting that efficiency is a good trait for a biotech company in any market.

The candid conversation on Thursday was part of Meeting on the Mesa, an annual cell and gene therapy conference held in Carlsbad, in the north of San Diego County. And it provided a glimpse into discussions happening across the life science industry as biotech markets continue a sharp slump that dates back to late 2021.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Unicorn down: Following layoffs, Biofourmis CEO quietly departs

WSS

Naloxone nonprofit donates 200,000 doses after FDA approval

Radiation, mainstay of cancer treatment, begins a fade

AstraZeneca challenges Medicare drug negotiation program

AstraZeneca bets AAV gene therapy will still deliver the goods

Listen: Merck v. USA, the best of ASCO, and Leqembi at the FDA

Medicare explains how it will choose drugs for negotiation

focus

Wikipedia

hotspot

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Jack Smith previously got search warrant for Trump's Twitter, new court docs show

Activists slam private health insurers over coverage restrictions

Naloxone nonprofit donates 200,000 doses after FDA approval

Peter Hotez and the public health issue of online harassment

Anavex keeps shifting the goalposts in its clinical trials

What does generative AI mean for health care? We asked experts

Complete sequence of Y chromosome published for first time

After affirmative action ruling, medical educators look to 'holistic review'

Drastic changes should bring profitability, startup health insurers say

leisure time

2024 GOP presidential candidates spar over abortion in debate

AstraZeneca bets AAV gene therapy will still deliver the goods

FDA panel issues narrow recommendation for Covid vaccine booster doses

Police still searching for prisoner who escaped from NYC hospital

For Cytokinetics, FDA rejection of heart drug would help, not hinder

What AAP's gender

hotspot

hotspot

leisure time

explore